Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Rapid correction of low vitamin D status in nursing home residents 3. 2008 Exclusive Survey—Earnings: Good news for primary care income 4. Medicare pay-for-reporting effort draws fire from frustrated doctors 5. Allopurinol-induced recurrent dress syndrome: Pathophysiology and treatment
Top Ten Searches
rheumatoid arthritis lupus polymyalgia sjogrens fibromyalgia amyloidosis vasculitis urate raynauds myositisYour Article Summary
See Latest ArticlesTreatment of polymyalgia rheumatica
Archives of Internal Medicine, 11/10/09
Hernández-Rodríguez J et al. – The scarcity of randomized trials and the high level of heterogeneity of studies on PMR therapy do not allow firm conclusions to be drawn. However, PMR remission seems to be achieved with prednisone treatment at a dose of 15 mg/d in most patients, and reductions below 10 mg/d should preferably follow a tapering rate of less than 1 mg/mo. Methotrexate seems to exert glucocorticoid-sparing properties.
Methods- Searched Cochrane Databases and MEDLINE (1957 through December 2008) for English-language articles on PMR treatment (randomized trials, prospective cohorts, case-control trials, and case series) that included 20 or more patients
- All data on study design, PMR definition criteria, medical therapy, and disease outcomes using a standardized protocol
- 30 studies (13 randomized trials and 17 observational studies) analyzed
- No meta-analyses or systematic reviews found
- PMR definition criteria, treatment protocols, and outcome measures differed widely among trials
- Starting prednisone doses higher than 10 mg/d associated with fewer relapses and shorter therapy than were lower doses
- Starting prednisone doses of 15 mg/d or lower associated with lower cumulative glucocorticoid doses than higher starting prednisone doses
- Starting prednisone doses higher than 15 mg/d associated with more glucocorticoid-related adverse effects
Today in Clinical Pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Effect of alendronate on bone metabolic indices and bone mineral density in patients treated with high-dose glucocorticoid: A prospective study
Osteoporosis International, 11/25/09
Treatment of osteoporosis: Recognizing and managing cutaneous adverse reactions and drug-induced hypersensitivity
Osteoporosis International, 11/25/09
Urinary deoxypyridinoline is a BMD-independent marker for prevalent vertebral fractures in postmenopausal women treated with glucocorticoid
Osteoporosis International, 11/25/09
Today in Rheumatoid Arthritis...keeping you current
Receive free subspecialty "5-minute updates" via email
CTLA4-Ig interacts with cultured synovial macrophages from rheumatoid arthritis patients and downregulates cytokine production
Arthritis Research & Therapy, 11/25/09
Type I interferons have no major influence on humoral autoimmunity in rheumatoid arthritis
Rheumatology, 11/25/09
Vaspin and omentin: new adipokines differentially regulated at the site of inflammation in rheumatoid arthritis
Annals of Rheumatic Diseases, 11/24/09
Sponsor
Article Search
Sponsor